{
  "docId": "019de073-389e-7133-8add-42617e455ecd",
  "docSlug": "35864e552cd13aec6cb8a942f7003b9f",
  "documentTitle": "AbCellera | Results Presentation Deck | 17 slides",
  "authorId": "abcellera",
  "authorName": "AbCellera",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-08-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 9,
  "pageCount": 17,
  "prevPage": 8,
  "nextPage": 10,
  "slideType": "key_takeaways",
  "function": "summarize",
  "density": "dense",
  "nDataPoints": 3,
  "notes": "The slide uses a high-contrast green-on-dark-blue color scheme to emphasize key metrics.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de073-389e-7133-8add-42617e455ecd/9",
  "deckHref": "/decks/019de073-389e-7133-8add-42617e455ecd",
  "deckJsonHref": "/decks/019de073-389e-7133-8add-42617e455ecd.json",
  "deckAnchorHref": "/decks/019de073-389e-7133-8add-42617e455ecd#slide-9",
  "components": [
    {
      "bbox": {
        "h": 0.28,
        "w": 0.46,
        "x": 0.46,
        "y": 0.53
      },
      "kind": "callout",
      "text": "Bamlanivimab was the first antibody to be authorized by FDA, and bebtelovimab continues to be used to combat the virus, remains effective against all known variants of concern, and is still the most potent COVID-19 antibody treatment available.",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0acb698a-db3d-43ed-ac41-64acf6e13519",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.55,
        "x": 0.08,
        "y": 0.16
      },
      "kind": "metric",
      "text": "2 YEARS OF TECH DEVELOPMENT\n2 COVID ANTIBODY TREATMENTS\n2.5M+ PATIENTS TREATED",
      "attrs": null,
      "subkind": "big-number",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3f651536-f28a-4268-9805-0eb79572b3ea",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.35,
        "x": 0.08,
        "y": 0.62
      },
      "kind": "paragraph",
      "text": "We had spent 2 years developing our technology specifically for pandemic response prior to the emergence of COVID-19 and initiated our work before entering into a partnership with Eli Lilly.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a5fc2ef5-adad-4720-845b-4bd6df8e7d55",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.45,
        "x": 0.08,
        "y": 0.06
      },
      "kind": "title",
      "text": "TECHNOLOGY DEVELOPMENT. VALUE OF PRE-PARTNERED PROGRAMS",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "70d5cb8c-e5a8-44f3-9452-92a6b1eb32fb",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 14,
      "from": 6,
      "beatId": "2e5d2b81-8307-4938-84ba-0e67309a2d6c",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "KPI Overview",
      "beatSlug": null,
      "evidence": "The presentation includes multiple slides with KPI overviews, showcasing the company's performance.",
      "position": 3,
      "confidence": 0.8,
      "parentBeatName": null,
      "parentBeatSlug": null
    }
  ],
  "loops": [
    {
      "to": 9,
      "from": 7,
      "name": "Golden Circle",
      "slug": "11-golden-circle",
      "bestFor": "Visionary leadership, brand positioning, mission statements",
      "matchId": "19a279ed-4e36-45cc-9e86-bf5a6d5da5c5",
      "evidence": "The thesis headline and key messages slides describe the company's technology and potential value.",
      "position": 1,
      "objective": "Explain the company's technology and value proposition",
      "structure": "The Why (Belief) -> The How (Process) -> The What (Result)",
      "confidence": 0.7,
      "description": "Invert the typical pitch by starting with why you exist, rather than what you do"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}